Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma 30 בספטמבר 2010 16:57 אין תגובות Alice L. Yu, M.D., Ph.D et al., N Engl J Med 2010; 363:1324-1334 קרא עוד ←
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma 30 בספטמבר 2010 16:31 אין תגובות Alice L. Yu, M.D., Ph.D. et al. N Engl J Med 2010; 363:1324-1334 קרא עוד ←
AEWS07P1 – A Pilot Study of Chemotherapy Intensification by Adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors 29 ביולי 2010 13:13 אין תגובות STUDY CHAIR Leo Mascarenhas, M.D. קרא עוד ←
Recent Advances in Neuroblastoma 10 ביוני 2010 16:49 אין תגובות John M. Maris, M.D N Engl J Med 2010; 362:2202-2211 קרא עוד ←
AGCT0132 | A PHASE III STUDY OF REDUCED THERAPY IN THE TREATMENT OF CHILDREN WITH LOW AND INTERMEDIATE RISK EXTRACRANIAL GERM CELL TUMORS 12 באפריל 2010 12:29 אין תגובות STUDY CHAIR: A. Lindsay Frazier, M.D., Sc.M. קרא עוד ←
EsPhALL: Amendment proposal 25 במרץ 2010 14:08 אין תגובות An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ קרא עוד ←
Neuroblastoma 9 בדצמבר 2009 16:09 אין תגובות Natia Esiashvili MD, Cynthia Anderson MD, Howard M.Katzenstein MD Current Problems in Cancer Volume 33, Issue 6, November–December 2009, Pages 333-360 קרא עוד ←
EsPhALL: EUDRACT-n° 2004-001647-30 1 בדצמבר 2009 14:14 אין תגובות An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ קרא עוד ←
NRSTS 2005 – a protocol for Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas 1 בספטמבר 2009 15:51 אין תגובות EpSSG NRSTS 2005 protocol Version 1.1 קרא עוד ←
Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma 7 בספטמבר 2008 15:36 אין תגובות ACNS0232 A Phase III Group-Wide Study STUDY CHAIR: Jeffrey C. Allen, M.D. קרא עוד ←